# ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Canonical URL: https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules
Ticker: ALXO
Company: ALX Oncology
Source: ALX Oncology
Published: 2026-04-17 20:05 EST
Original Source URL: https://ir.alxoncology.com
## Summary

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of

## Article Body
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of
## Recent Company News
- 2026-06-01 12:00 EST — [ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/ALXO/alx-oncology-to-present-at-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: ALX Oncology
- 2026-05-08 12:00 EST — [ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: ALX Oncology
- 2026-05-07 12:00 EST — [ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression](https://biopharmsignal.com/news/ALXO/alx-oncology-s-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression) — Source: ALX Oncology
- 2026-04-30 12:01 EST — [ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026](https://biopharmsignal.com/news/ALXO/alx-oncology-announces-that-cd47-biomarker-data-from-clinical-trial-evaluating-evorpacept-zanidatamab-combination-in-advanced-breast-cancer-will-be-presented-at-esmo-breast-cancer-2026) — Source: ALX Oncology
- 2026-04-17 20:05 EST — [ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules](https://biopharmsignal.com/news/ALXO/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules) — Source: ALX Oncology
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)